CTS will implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The newly licensed Geenius test is an immunochromatographic assay designed to confirm and differentiate individual antibodies to Human Immunodeficiency Virus Types 1 and 2. The assay will be replacing the HIV-1 Western blot and HIV-2 EIA assays which are performed on samples with a reactive result on a licensed HIV 1/2 screening test.
Read all about it on the Communication page by clicking this link: Communications
The CTS Medical Advisory Board recently agreed upon a revision to our standard testing algorithm. Th...
CTS Spotlight at 2018 AABB Annual Meeting Sunday, October 14, 2018 at 1:30 PM: Scientific Oral ...
In response to the FDA guidance document for Babesia, CTS will implement the licensed Grifols ...
As communicated on January 21, 2020, CTS will implement the licensed Grifols Babesia test for sample...
The Q & A document from the Reentry Changes Webinar hosted on 06/06/18 has been posted in the Wh...
CTS was recently notified that one of the tubes listed in the Sample Acceptability document...